此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock (UNIRING-OBS SH)

Prospective Multicenter Observational Comparative Cohort Study of Actual UNIFUZOL® (Arginine Sodium Succinate) Versus Lactated Ringer's Use in Adults With Urinary- or Pulmonary-Source Sepsis During the Early Stabilization/Resolving Phase of Septic Shock and Documented Lower-Extremity Atherosclerotic Disease: Peripheral Perfusion, NIRS Vascular Reactivity, and Macro-Microhemodynamic Coherence

Peripheral Perfusion After UNIFUZOL® Versus Lactated Ringer's in Resolving Septic Shock

研究概览

研究类型

观察性的

注册 (估计的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Alexey Kovalenko, Doc Biol Sci
  • 电话号码:212 +78127108225
  • 邮箱:science@polysan.ru

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Adults treated in participating intensive care units for urinary- or pulmonary/respiratory-source sepsis with current or recently documented septic shock, documented lower-extremity atherosclerotic peripheral artery disease, early hemodynamic stabilization, ongoing hypoperfusion, and PiCCO Plus already in place for clinical indications. Potentially eligible participants are screened consecutively during active recruitment periods.

描述

Inclusion Criteria:

  • Age 18 years or older.
  • Septic shock by Sepsis-3 currently or documented within the previous 24 hours.
  • Urinary or pulmonary/respiratory suspected or confirmed infection source.
  • Documented atherosclerotic disease of the lower-extremity arteries.
  • Mean arterial pressure at least 65 mm Hg with norepinephrine less than 0.2 micrograms/kg/min and no increase greater than 20 percent or new vasopressor during the previous 30 minutes.
  • PiCCO Plus already installed for clinical indications and technically usable.
  • At least one ongoing sign of hypoperfusion or microcirculatory dysfunction defined in the protocol.
  • Before any study-specific baseline procedure, the treating physician has independently decided that an additional crystalloid infusion is clinically indicated and has selected UNIFUZOL® or lactated Ringer's solution.
  • Thenar NIRS-VOT can be performed safely.
  • Informed consent or another ethics-board-approved consent process is completed before study-specific procedures.

Exclusion Criteria:

  • Hemorrhagic, cardiogenic, or obstructive shock as the leading cause of instability.
  • Rapidly increasing vasopressor requirement or need for immediate hemodynamic rescue inconsistent with the protocol-defined stabilization phase.
  • Clinically important fluid overload/pulmonary edema for which the treating physician considers additional fluid contraindicated; severe unstable ARDS.
  • Active major bleeding or another condition requiring urgent therapy that prevents standardized baseline assessment.
  • Expected survival less than 24 hours or limitation of intensive treatment.
  • Pregnancy or breastfeeding.
  • Participation in an interventional study expected to materially affect hemodynamics.
  • Contraindication to any component of the physician-selected fluid.
  • Upper-limb ischemia, severe Raynaud phenomenon, local thenar skin injury, or another condition making NIRS-VOT unsafe or uninterpretable.
  • Core temperature below 34 degrees Celsius.
  • Acute/critical lower-extremity ischemia requiring urgent vascular treatment or severely compromising peripheral assessments.
  • Unable to establish Tdecision/T0 or obtain pre-infusion baseline CRT; inability to obtain pre-infusion ReOx excludes the participant from the key NIRS analysis.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:CASE_CONTROL
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
UNIFUZOL® exposure cohort

Participants for whom the treating physician independently selected and actually started UNIFUZOL® at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

Lactated Ringer's exposure cohort

Participants for whom the treating physician independently selected and actually started lactated Ringer's solution at T0. The protocol does not determine indication, dose, rate, duration, repeat administration, or subsequent fluids.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Capillary Refill Time at 6 Hours
大体时间:6 hours after start (window ±60 minutes)

Capillary refill time (CRT) in seconds measured using a standardized distal-finger technique. Two valid measurements are averaged; if they differ by more than 1.0 second, a third measurement is obtained and the median of three is used. The primary statistical comparison adjusts for strictly pre-infusion CRT and prespecified baseline covariates. Lower CRT is considered physiologically favorable.

6 hours after start (window ±60 minutes)

次要结果测量

结果测量
措施说明
大体时间
Thenar NIRS Reoxygenation Slope at 6 Hours
大体时间:6 hours after start (window ±60 minutes)

Post-occlusion reoxygenation slope (ReOx) derived from a standardized thenar near-infrared spectroscopy vascular occlusion test using a frozen common device/software/analysis algorithm. ReOx is analyzed continuously in percent StO2 per second and adjusted for pre-infusion ReOx. Higher ReOx is considered physiologically favorable.

6 hours after start (window ±60 minutes)
Sustained Macro-Microhemodynamic Coherent Response
大体时间:6 and 12 hours after start

Protocol-defined supportive composite outcome. This measure is reported as a single binary value (Yes/No), which is considered achieved only if ALL of the following criteria are simultaneously met: full macrohemodynamic stability, peripheral/microvascular recovery, and pulmonary/volume safety at both 6 and 12 hours. The composite is not a validated diagnostic criterion and is analyzed as supportive/exploratory.

6 and 12 hours after start
Change in Capillary Refill Time Over 24 Hours
大体时间:From start through 24 hours

Serial CRT at 60 minutes, approximately 2 hours/end of infusion, 6 hours, 12 hours, and 24 hours; analyses include continuous change and trajectory models.

From start through 24 hours
Change in ReOx
大体时间:From pre-infusion baseline through 24 hours

Serial ReOx from standardized NIRS-VOT.

From pre-infusion baseline through 24 hours
Change in De-oxygenation slope
大体时间:From pre-infusion baseline through 24 hours

DeOx from standardized NIRS-VOT (%/min).

From pre-infusion baseline through 24 hours
Change in NIRS Vascular Reactivity Over 24 Hours (tissue oxygenation)
大体时间:From pre-infusion baseline through 24 hours

Tissue oxygenation variables (%)

From pre-infusion baseline through 24 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:K.M. Lebedinsky、North-Western State Medical University named after I.I.Mechnikov
  • 首席研究员:I. S. Simutis、Adult Intensive Care Unit, L.G. Sokolov North-Western District Scientific and Clinical Center, FMBA of Russia, St Petersburg, Russian Federation
  • 首席研究员:A.Yu. Yakovlev、City Hospital No. 38 named after N.A. Semashko

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月16日

初级完成 (估计的)

2028年11月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年9月21日

首先提交符合 QC 标准的

2026年11月17日

首次发布 (实际的)

2026年11月19日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅